The approval is based on a phase 2 trial showing that Libtayo achieved a response in 29% of patients ... although the picture may not be quite so simple. On its own, Keytruda cut the risk of ...

with a duration of response of 16 months versus seven months, respectively. Libtayo – the sixth PD-L/PD-L1 inhibitor to reach the market – is already approved to treat newly-diagnosed advanced ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...